rec2

You may have missed

Deux premiers patients atteints de leucémie ont reçu la thérapie SMART101 de Smart Immune dans le cadre de l’essai ReSET-02 de phase I/II

Smart Immune Doses First Leukemia Patients with ProTcell Therapy SMART101 in ReSET-02 Phase I/II Trial

BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD

Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen at NAMS 2023

ObsEva Files half Year 2023 Financial Statements

error: Content is protected !!